Riken Vitamin Co., Ltd.
Notice Regarding the Status and Completion of Treasury Stock Acquisition (Based on the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)
Between March 1 and March 23, 2026, 53,300 shares of treasury stock were acquired for a total of 156,067,693 yen, bringing the cumulative acquisition total to 696,500 shares with a total acquisition cost of 1,999,887,013 yen, and the acquisition has been completed.
Key Figures
- Total number of shares acquired (as of March 23, 2026): 696,500 shares
- Total acquisition cost (as of March 23, 2026): 1,999,887,013 yen
- Shares acquired this time: 53,300 shares (March 1–23, 2026)
AI要約
Overview of Treasury Stock Acquisition
Riken Vitamin Co., Ltd. conducted treasury stock acquisition pursuant to the resolution of the Board of Directors on April 30, 2025, based on the provisions of Article 165, Paragraph 3 of the Companies Act. The target was common shares, and from March 1 to March 23, 2026, 53,300 shares were acquired at a total acquisition cost of 156,067,693 yen. As a result, the cumulative number of shares acquired reached 696,500, with a total acquisition cost of 1,999,887,013 yen, completing the treasury stock acquisition based on the Board of Directors’ resolution.
Impact on Shareholders and Future Outlook
This treasury stock acquisition was implemented with a maximum limit of 3.34% of the total number of issued shares, and the acquisition cost limit was set at 2 billion yen. With the completion of the acquisition, it is expected to improve capital efficiency as part of shareholder returns. While future capital policies remain unclear at this point, the report of completion ensures transparency to the market.
